[{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-81201887","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-101","moa":"||LCA1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allermi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"||ACh receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Inapplicable"},{"orgOrder":0,"company":"Allermi","sponsor":"Lucas Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Triamcinolone","moa":"||ACh receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Lucas Venture Group","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Lucas Venture Group"},{"orgOrder":0,"company":"Allermi","sponsor":"Nelstone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Financing","leadProduct":"Triamcinolone","moa":"||ACh receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Nelstone Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Nelstone Ventures"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Inapplicable"},{"orgOrder":0,"company":"ACOM Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"ACOM Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ACOM Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ACOM Labs \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Kenacort, Tri-Nasal, Triaderm, Azmacort, Triamcinolone

Kenacort, Tri-Nasal, Triaderm, Azmacort, Triamcinolone
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Kenacort, Tri-Nasal, Triaderm, Azmacort, Triamcinolone

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

36 API Suppliers, 8 USDMF, 4 CEP/COS, 1 JDMF, 4 EU WC, 7 KDMF, 4 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

FINISHED DOSAGE FORMULATIONS

76 FDF Dossiers, 27 FDA Orange Book, 37 Europe, 6 Australia, 4 South Africa, 2 Listed Dossiers

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 2 SPI Pharma, 1 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 3 Actylis, 1 BASF, 1 Finar, 1 Pluviaendo, 11 Roquette, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

10 Film Formers & Plasticizers, 7 Parenteral, 5 Topical, 5 Fillers, Diluents & Binders, 4 Taste Masking, 4 Coating Systems & Additives, 2 Chewable & Orodispersible Aids, 1 Solubilizers, 1 Thickeners and Stabilizers, 1 Co-Processed Excipients, 1 Direct Compression, 1 Soft Gelatin

DIGITAL CONTENT

21 News #PharmaBuzz

21 News #PharmaBuzz

GLOBAL SALES INFORMATION

34 Regulatory FDF Prices

34 Regulatory FDF Prices

MARKET PLACE

4 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 1 JP

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Triamcinolone,Inapplicable

Therapeutic Area : Immunology

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study to Assess Efficacy and Safety of NasacortÂ® Nasal Spray in Comparison With FlixonaseÂ® Nasal Spray...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Steroid

Upfront Cash : Inapplicable

October 23, 2017

Lead Product(s) : Triamcinolone,Inapplicable

Therapeutic Area : Immunology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Atsena Therapeutics

U.S.A

EPSC

Not Confirmed

03

ACOM Labs

Country

EPSC

Not Confirmed

04

Johnson & Johnson Innovative Medicine

U.S.A

EPSC

Not Confirmed

05

Allermi

U.S.A

EPSC

Not Confirmed

06

Allermi

U.S.A

EPSC

Not Confirmed

07

Allermi

U.S.A

EPSC

Not Confirmed

08

Endeavor Health

Country

EPSC

Not Confirmed

09

Kettering Health Network

Country

EPSC

Not Confirmed

10

Johns Hopkins University

Country

EPSC

Not Confirmed

1
2